Cytokine therapy of tuberculosis at the crossroads

References

• Trapero-Marugan M, Garcia-Buey L, Munoz C et al. Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. Aliment. Pharmacol. Ther.24, 117–128 (2006).
   PubMedGoogle Scholar
• Asnis GM, De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J. Clin. Gastroenterol.40, 322–335 (2006).
   PubMed Web of Science ®Google Scholar
• Gallin JI. Interferon-γ in the management of chronic granulomatous-disease. Rev. Infect. Dis.13, 973–978 (1991).
   PubMedGoogle Scholar
• Marciano BE, Wesley R, De Carlo ES et al. Long-term interferon-γ therapy for patients with chronic granulomatous disease. Clin. Infect. Dis.39, 692–699 (2004).
   PubMed Web of Science ®Google Scholar
• Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-γ in patients with chronic granulomatous-disease – European follow-up-study. Eur. J. Pediatr.154, 295–298 (1995).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Bustamante B, Ticona E et al. Recombinant interferon-γ 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis.189, 2185–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Roilides E. Cytokines and fungal infections. Br. J. Haematol.129, 583–596 (2005).
   PubMed Web of Science ®Google Scholar
• Flynn TN, Kelsey SM, Hazel DL, Guest JF. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy – treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. Pharmacoeconomics16, 543–550 (1999).
   PubMedGoogle Scholar
• Holland SM, Eisenstein EM, Kuhns DB et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon-γ – a preliminary-report. N. Engl. J. Med.330, 1348–1355 (1994).
   PubMed Web of Science ®Google Scholar
• Chatte G, Panteix G, Perrinfayolle M, Pacheco Y. Aerosolized interferon-γ for Mycobacterium avium-complex lung-disease. Am. J. Resp. Crit. Care Med.152, 1094–1096 (1995).
   PubMedGoogle Scholar
• Kemper CA, Bermudez LE, Deresinski SC, Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte–macrophage colony-stimulating factor. J. Infect. Dis.177, 914–920 (1998).
   PubMedGoogle Scholar
• Kedzierska K, Mak J, Mijch A et al. Granulocyte–macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivo. J. Infect. Dis.181, 390–394 (2000).
   PubMed Web of Science ®Google Scholar
• Cinti S, Coffey M, Sullivan A, Kazanjian P. Killing of Mycobacterium avium by neutrophils and monocytes from AIDS patients treated with recombinant granulocyte–macrophage colony-stimulating factor. J. Infect. Dis.180, 229–233 (1999).
   PubMed Web of Science ®Google Scholar
• Lauw FN, van der Meer JTM, de Metz J, Danner SA, van der Poll T. No beneficial effect of interferon-γ treatment in 2 human immunodeficiency virus-infected patients with Mycobacterium avium complex infection. Clin. Infect. Dis.32, E81–E82 (2001).
   Google Scholar
• Sekiguchi Y, Yasui K, Yamazaki T, Agematsu K, Kobayashi N, Koike K. Effective combination therapy using interferon-γ and interleukin-2 for disseminated Mycobacterium avium complex infection in a pediatric patient with AIDS. Clin. Infect. Dis.41, 104–106 (2005).
   Google Scholar
• Ward CM, Jyonouchi H, Kotenko SV et al. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon α-2b in a patient with complete interferon-γ receptor R1 deficiency. Eur. J. Pediatr.166, 981–985 (2007).
   PubMedGoogle Scholar
• de Silva TI, Cope A, Goepel J, Greig JM. The use of adjuvant granulocyte–macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection. J. Infect.54, 207–210 (2007).
   PubMed Web of Science ®Google Scholar
• Milanes-Virelles MT, Garcia-Garcia I, Santos-Herrera Y et al. Adjuvant interferon γ in patients with pulmonary atypical mycobacteriosis: a randomized, double-blind, placebo-controlled study. BMC Infect. Dis.8, 17 (2008).
   PubMedGoogle Scholar
• Toossi Z. The inflammatory response in Mycobacterium tuberculosis infection. Arch. Immunol. Ther. Exp.48, 513–519 (2000).
   PubMedGoogle Scholar
• Vankayalapati R, Wizel B, Weis SE et al. Serum cytokine concentrations do not parallel Mycobacterium tuberculosis-induced cytokine production in patients with tuberculosis. Clin. Infect. Dis.36, 24–28 (2003).
   PubMedGoogle Scholar
• Tomioka H. Adjunctive immunotherapy of mycobacterial infections. Curr. Pharm. Des.10, 3297–3312 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin. Infect. Dis.41, 201–208 (2005).
   PubMed Web of Science ®Google Scholar
• Holland SM. Cytokine therapy of mycobacterial infections. Adv. Intern. Med.45, 431–452 (2000).
   PubMedGoogle Scholar
• Reljic R. IFN-γ therapy of tuberculosis and related infections. J. Interferon Cytokine Res.27, 353–363 (2007).
   PubMed Web of Science ®Google Scholar
• Lederer JA, Perez VL, DesRoches L, Kim SM, Abbas AK, Lichtman AH. Cytokine transcriptional events during helper T cell subset differentiation. J. Exp. Med.184, 397–406 (1996).
   PubMed Web of Science ®Google Scholar
• Yoshida A, Koide Y, Uchijima M, Yoshida TO. IFN-γ induces IL-12 messenger-RNA expression by a murine macrophage cell-line, J774. Biochem. Biophys. Res. Comm.198, 857–861 (1994).
   PubMed Web of Science ®Google Scholar
• Liew FY, Li Y, Severn A et al. A possible novel pathway of regulation by murine T-helper type-2 (Th2) cells of a Th1 cell-activity via the modulation of the induction of nitric-oxide synthase on macrophages. Eur. J. Immunol.21, 2489–2494 (1991).
   PubMed Web of Science ®Google Scholar
• Darnell JE, Kerr IM, Stark GR. JAK–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science264, 1415–1421 (1994).
   PubMed Web of Science ®Google Scholar
• Ihle JN. STATs: signal transducers and activators of transcription. Cell84, 331–334 (1996).
   PubMed Web of Science ®Google Scholar
• Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Annu. Rev. Immunol.15, 749–795 (1997).
   PubMed Web of Science ®Google Scholar
• Honda K, Takaoka A, Taniguchi T. Type I inteferon gene induction by the interferon regulatory factor family of transcription factors. Immunity25, 349–360 (2006).
   PubMed Web of Science ®Google Scholar
• Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon-γ gene-disrupted mice. J. Exp. Med.178, 2243–2247 (1993).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med.178, 2249–2254 (1993).
   PubMed Web of Science ®Google Scholar
• Mansouri D, Adimi P, Mirsaeidi M et al. Inherited disorders of the IL-12–IFN-γ axis in patients with disseminated BCG infection. Eur. J. Pediatr.164, 753–757 (2005).
   PubMed Web of Science ®Google Scholar
• Remiszewski P, Roszkowska-Sliz B, Winek J et al. Disseminated Mycobacterium avium infection in a 20-year-old female with partial recessive IFN γ R1 deficiency. Respiration73, 375–378 (2006).
   PubMedGoogle Scholar
• Seneviratne SL, Doffinger R, Macfarlane J et al. Disseminated Mycobacterium tuberculosis infection due to interferon γ deficiency. Response to replacement therapy. Thorax62, 97–99 (2007).
   PubMedGoogle Scholar
• Raad I, Hachem R, Leeds N, Sawaya R, Salem Z, Atweh S. Use of adjunctive treatment with interferon-γ in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Clin. Infect. Dis.22, 572–574 (1996).
   PubMedGoogle Scholar
• Condos R, Raju B, Canova A et al. Recombinant γ interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect. Immun.71, 2058–2064 (2003).
   PubMed Web of Science ®Google Scholar
• Kamijo R, Le JM, Shapiro D et al. Mice that lack the interferon-γ receptor have profoundly altered responses to infection with bacillus-Calmette–Guerin and subsequent challenge with lipopolysaccharide. J. Exp. Med.178, 1435–1440 (1993).
   PubMed Web of Science ®Google Scholar
• Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet349, 1513–1515 (1997).
   PubMed Web of Science ®Google Scholar
• Koh WJ, Kwon OJ, Suh GY et al. Six-month therapy with aerosolized interferon-γ for refractory multidrug-resistant pulmonary tuberculosis. J. Korean Med. Sci.19, 167–171 (2004).
   PubMed Web of Science ®Google Scholar
• Gilks CF, Brindle RJ, Otieno LS et al. Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical-services in Nairobi. AIDS4, 981–985 (1990).
   PubMedGoogle Scholar
• Ulrichs T, Fieschi C, Nevicka E et al. Variable outcome of experimental interferon-γ therapy of disseminated bacillus Calmette–Guerin infection in two unrelated interleukin-12R β 1-deficient Slovakian children. Eur. J. Pediatr.164, 166–172 (2005).
   PubMedGoogle Scholar
• Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N et al. Adjuvant interferon γ in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect. Dis.4, 44(2004).
   PubMed Web of Science ®Google Scholar
• Park SK, Cho S, Lee IH et al. Subcutaneously administered interferon-γ for the treatment of multidrug-resistant pulmonary tuberculosis. Int. J. Infect. Dis.11, 434–440 (2007).
   PubMedGoogle Scholar
• Coulter JBS, Baretto RL, Mallucci CL et al. Tuberculous meningitis: protracted course and clinical response to interferon-γ. Lancet Infect. Dis.7, 225–232 (2007).
   PubMedGoogle Scholar
• Hussain S, Zwilling BS, Lafuse WP. Mycobacterium avium infection of mouse macrophages inhibits IFN-γ Janus kinase–STAT signaling and gene induction by down-regulation of the IFN-γ receptor. J. Immunol.163, 2041–2048 (1999).
   PubMedGoogle Scholar
• Wojciechowski W, DeSanctis J, Skamene E, Radzioch D. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette–Guerin involves class II transactivator and depends on the Nramp1 gene. J. Immunol.163, 2688–2696 (1999).
   PubMedGoogle Scholar
• Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin. Infect. Dis.40, S131–S235 (2005).
   Web of Science ®Google Scholar
• Murray HW. Interferon-γ and host antimicrobial defense – current and future clinical-applications. Am. J. Med.97, 459–467 (1994).
   PubMed Web of Science ®Google Scholar
• Steinmann GG, Rosenkaimer F, Leitz G. Clinical-experiences with interferon-α and interferon-γ. Int. Rev. Exp. Pathol.34, 193–207 (1993).
   PubMedGoogle Scholar
• Panitch HS, Haley AS, Hirsch RL, Johnson KP. Exacerbations of multiple-sclerosis in patients treated with γ interferon. Lancet1, 893–895 (1987).
   PubMed Web of Science ®Google Scholar
• Murray HW. Interferon-γ, the activated macrophage, and host defense against microbial challenge. Ann. Intern. Med.108, 595–608 (1988).
   PubMed Web of Science ®Google Scholar
• Briken V, Porcelli SA, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol. Microbiol.53, 391–403 (2004).
   PubMed Web of Science ®Google Scholar
• Ryll R, Kumazawa Y, Yano I. Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids – a review. Microbiol. Immunol.45, 801–811 (2001).
   PubMed Web of Science ®Google Scholar
• Strohmeier GR, Fenton MJ. Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect.1, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Jankovic D, Sher A, Yap G. Th1/Th2 effector choice in parasitic infection: decision making by committee. Curr. Opin. Immunol.13, 403–409 (2001).
   PubMedGoogle Scholar
• Altare F, Durandy A, Lammas D et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science280, 1432–1435 (1998).
   PubMed Web of Science ®Google Scholar
• de Jong R, Altare F, Haagen IA et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science280, 1435–1438 (1998).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. IL-12 Increases resistance of Balb/C mice to Mycobacterium tuberculosis infection. J. Immunol.155, 2515–2524 (1995).
   PubMed Web of Science ®Google Scholar
• Silva RA, Pais TF, Appelberg R. Evaluation of IL-12 in immunotherapy and vaccine design in experimental Mycobacterium avium infections. J. Immunol.161, 5578–5585 (1998).
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kasama T, Yamazaki J et al. Protection of mice from Mycobacterium avium infection by recombinant interleukin-12. Antimicrob. Agents Chemother.39, 1369–1371 (1995).
   PubMed Web of Science ®Google Scholar
• Nolt D, Flynn JL. Interleukin-12 therapy reduces the number of immune cells and pathology in lungs of mice infected with Mycobacterium tuberculosis. Infect. Immun.72, 2976–2988 (2004).
   PubMed Web of Science ®Google Scholar
• Marchant A, Amedei A, Azzurri A et al. Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-α or interleukin-12. Am. J. Respir. Cell Mol. Biol.24, 187–194 (2001).
   PubMed Web of Science ®Google Scholar
• Feng CG, Jankovic D, Kullberg M et al. Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J. Immunol.174, 4185–4192 (2005).
   PubMed Web of Science ®Google Scholar
• Holscher C, Atkinson RA, Arendse B et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. J. Immunol.167, 6957–6966 (2001).
   PubMed Web of Science ®Google Scholar
• Ha SJ, Park SH, Kim HJ et al. Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination. Infect. Immun.74, 4954–4959 (2006).
   PubMed Web of Science ®Google Scholar
• Greinert U, Ernst M, Schlaak M, Entzian P. Interleukin-12 as successful adjuvant in tuberculosis treatment. Eur. Resp. J.17, 1049–1051 (2001).
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood90, 2541–2548 (1997).
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity13, 715–725 (2000).
   PubMed Web of Science ®Google Scholar
• Wozniak TM, Ryan AA, Triccas JA, Britton WJ. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect. Immun.74, 557–565 (2006).
   PubMed Web of Science ®Google Scholar
• Happel KI, Lockhart EA, Mason CM et al. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect. Immun.73, 5782–5788 (2005).
   PubMed Web of Science ®Google Scholar
• Peng MY, Wang ZH, Yao CY et al. Interleukin 17-producing γ δ T cells increased in patients with active pulmonary tuberculosis. Cell. Mol. Immunol.5, 203–208 (2008).
   PubMed Web of Science ®Google Scholar
• Devergne O, Hummel M, Koeppen H et al. A novel interleukin-12 p40-related protein induced by latent Epstein–Barr virus infection in B lymphocytes. J. Virol.70, 1143–1153 (1996).
   PubMed Web of Science ®Google Scholar
• Pflanz S, Timans JC, Cheung J et al. IL-27, a heterodimeric cytokine composed of EB13 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity16, 779–790 (2002).
   PubMed Web of Science ®Google Scholar
• Holscher C, Holscher A, Ruckerl D et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J. Immunol.174, 3534–3544 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tanaka T, Kita Y et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine24, 1191–1204 (2006).
   PubMed Web of Science ®Google Scholar
• Freidag BL, Melton GB, Collins F et al. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect. Immun.68, 2948–2953 (2000).
   PubMed Web of Science ®Google Scholar
• Palendira U, Kamath AT, Feng CG et al. Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis. Infect. Immun.70, 1949–1956 (2002).
   PubMed Web of Science ®Google Scholar
• Yu DH, Li M, Hu XD, Cai H. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Vaccine25, 6744–6754 (2007).
   PubMed Web of Science ®Google Scholar
• Martin E, Kamath AT, Briscoe H, Britton WJ. The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette–Guerin) in protecting against systemic Mycobacterim avium infection. Immunology109, 308–314 (2003).
   PubMed Web of Science ®Google Scholar
• Silva RA, Pais TF, Appelberg R. Effects of interleukin-12 in the long-term protection conferred by a Mycobacterium avium subunit vaccine. J. Immunol. (Scand.)52, 531–533 (2000).
   PubMed Web of Science ®Google Scholar
• Malek TR. The biology of interleukin-2. Annu. Rev. Immunol.26, 453–479 (2007).
   Google Scholar
• Davey RT, Chaitt DG, Piscitelli SC et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis.175, 781–789 (1997).
   PubMed Web of Science ®Google Scholar
• Hengge UR, Goos M, Esser S et al. Randomized, controlled Phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS12, F225–F234 (1998).
   PubMed Web of Science ®Google Scholar
• Sanchez FO, Rodriguez JI, Agudelo G, Garcia LF. Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls. Infect. Immun.62, 5673–5678 (1994).
   PubMed Web of Science ®Google Scholar
• Toossi Z, Ellner JJ. Interaction of Leu-11 reactive lymphocytes and adherent cells in suppression of Ppd-induced IL-2 production in tuberculosis. Clin. Res.34, A535 (1986).
   Google Scholar
• Toossi Z, Kleinhenz ME, Ellner JJ. Defective interleukin-2 production and responsiveness in human pulmonary tuberculosis. J. Exp. Med.163, 1162–1172 (1986).
   PubMed Web of Science ®Google Scholar
• Shiratsuchi H, Okuda Y, Tsuyuguchi I. Recombinant human interleukin-2 reverses in vitro-deficient cell-mediated immune-responses to tuberculin purified protein derivative by lymphocytes of tuberculous patients. Infect. Immun.55, 2126–2131 (1987).
   PubMedGoogle Scholar
• Jeevan A, Asherson GL. Recombinant interleukin-2 limits the replication of Mycobacterium-lepraemurium and Mycobacterium-bovis BCG in mice. Infect. Immun.56, 660–664 (1988).
   PubMed Web of Science ®Google Scholar
• Johnson BJ, Ress SR, Willcox P et al. Clinical and immune-responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol. Ther.1, 185–196 (1995).
   PubMedGoogle Scholar
• Johnson BJ, Bekker LG, Rickman R et al. RhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber. Lung Dis.78, 195–203 (1997).
   PubMedGoogle Scholar
• Johnson JL, Ssekasanvu E, Okwera A et al.; Uganda Case Western Reserve University. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am. J. Resp. Crit. Care Med.168, 185–191 (2003).
   PubMed Web of Science ®Google Scholar
• Barnes PF. Immunotherapy for tuberculosis – wave of the future or tilting at windmills? Am. J. Resp. Crit. Care Med.168, 142–143 (2003).
   PubMed Web of Science ®Google Scholar
• Chu NH, Zhu LZ, Yie ZZ et al. A controlled clinical study on the efficacy of recombinant human interleukin-2 in the treatment of pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi26, 548–551 (2003).
   PubMedGoogle Scholar
• Sakhno LV, Tikhonova MA, Ostanin AA, Nikonov SD, Zhdanov OA, Chernykh ER. Interleukin-2 in the correction of T-cell anergy in patients with pulmonary tuberculosis. Probl. Tuberk. Bolezn. Legk.1, 48–52 (2006).
   Google Scholar
• Skvortsova LA, Pavlova MV, Vinogradova TI, Archakova LI. Combined therapy of pulmonary tuberculosis by using recombinant interleukins. Probl. Tuberk. Bolezn. Legk.10, 9–12 (2003).
   Google Scholar
• Martinez-Moczygemba M, Huston DP. Biology of common β receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J. Allergy Clin. Immunol.112, 653–665 (2003).
   PubMed Web of Science ®Google Scholar
• Armitage JO. Emerging applications of recombinant human granulocyte–macrophage colony-stimulating factor. Blood92, 4491–4508 (1998).
   PubMed Web of Science ®Google Scholar
• Bermudez LE, Martinelli J, Petrofsky M, Kolonoski P, Young LS. Recombinant granulocyte–macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium-avium complex infection in the beige mouse model. J. Infect. Dis.169, 575–580 (1994).
   PubMedGoogle Scholar
• Onyeji CO, Nightingale CH, Tessier PR, Nicolau DP, Bow LM. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte–macrophage colony-stimulating factor against intramacrophage Mycobacterium-avium Mycobacterium-intracellulare. J. Infect. Dis.172, 810–816 (1995).
   PubMed Web of Science ®Google Scholar
• Kedzierska K, Maerz A, Warby T et al. Granulocyte–macrophage colony-stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages. AIDS14, 1739–1748 (2000).
   PubMedGoogle Scholar
• Pedral-Sampaio DB, Netto EM, Brites C et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. J. Infect. Dis. (Braz.)7, 245–252 (2003).
   PubMedGoogle Scholar
• Ryan AA, Wozniak TM, Shklovskaya E et al. Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette–Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. J. Immunol.179, 8418–8424 (2007).
   PubMed Web of Science ®Google Scholar
• Wang J, Zganiacz A, Xing Z. Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine20, 2887–2898 (2002).
   PubMed Web of Science ®Google Scholar
• Kamath AT, Hanke T, Briscoe H, Britton WJ. Co-immunization with DNA vaccines expressing granulocyte–macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. Immunology96, 511–516 (1999).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Chan J et al. Tumor-necrosis-factor-α is required in the protective immune-response against Mycobacterium-tuberculosis in mice. Immunity2, 561–572 (1995).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis.39, 1254–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis.38, 1261–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Tramontana JM, Utaipat U, Molloy A et al. Thalidomide treatment reduces tumor-necrosis-factor-α production and enhances weight-gain in patients with pulmonary tuberculosis. Mol. Med.1, 384–397 (1995).
   PubMed Web of Science ®Google Scholar
• Schoeman JF, Springer P, van Rensburg AJ et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J. Child Neurol.19, 250–257 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS18, 257–264 (2004).
   PubMed Web of Science ®Google Scholar
• Mayanja-Kizza H, Jones-Lopez E, Okwera A et al.; Uganda-Case Western Res Collaborat. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a Phase 2 clinical trial in Uganda. J. Infect. Dis.191, 856–865 (2005).
   PubMed Web of Science ®Google Scholar
• Rook GAW, Hernandez-Pando R, Dheda K, Seah GT. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol.25, 483–488 (2004).
   PubMed Web of Science ®Google Scholar
• Buccheri S, Reljic R, Caccamo N et al. IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice. Eur. J. Immunol.37, 729–737 (2007).
   PubMed Web of Science ®Google Scholar
• Roy E, Lowrie DB, Jolles SR. Current strategies in TB immunotherapy. Curr. Mol. Med.7, 373–386 (2007).
   PubMed Web of Science ®Google Scholar
• Hart TK, Blackburn MN, Brigham-Burke M et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol.130, 93–100 (2002).
   PubMed Web of Science ®Google Scholar
• Steinke JW, Borish L. Th2 cytokines and asthma interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Resp. Res.2, 66–70 (2001).
   PubMed Web of Science ®Google Scholar
• van Crevel R, Karyadi E, Preyers F et al. Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J. Infect. Dis.181, 1194–1197 (2000).
   PubMedGoogle Scholar
• Rook GAW, Dheda K, Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting? Vaccine23, 2115–2120 (2005).
   PubMed Web of Science ®Google Scholar
• Elias D, Akuffo H, Pawlowski A, Haile M, Schon T, Britton S. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine23, 1326–1334 (2005).
   PubMed Web of Science ®Google Scholar
• Demissie A, Wassie L, Abebe M et al. The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of γ interferon. Infect. Immun.74, 2817–2822 (2006).
   PubMedGoogle Scholar
• Silva RA, Pais TF, Appelberg R. Blocking the receptor for IL-10 improves antimycobacterial chemotherapy and vaccination. J. Immunol.167, 1535–1541 (2001).
   PubMedGoogle Scholar
• Kedzierska K, Paukovics G, Handley A et al. Interferon-γ therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals. HIV Clin. Trials5, 80–85 (2004).
   PubMed Web of Science ®Google Scholar
• Palmero D, Eiguchi K, Rendo P, Zorrilla LC, Abbate E, Montaner LJG. Phase II trial of recombinant interferon-α 2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int. J. Tuberc. Lung Dis.3, 214–218 (1999).
   PubMed Web of Science ®Google Scholar
• Giosue S, Casarini M, Ameglio F et al. Aerosolized interferon-α treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur. Cytokine Netw.11, 99–103 (2000).
   PubMed Web of Science ®Google Scholar
• Riddell LA, Pinching AJ, Hill S et al. A Phase III study of recombinant human interferon γ to prevent opportunistic infections in advanced HIV disease. AIDS Res. Hum. Retroviruses17, 789–797 (2001).
   PubMed Web of Science ®Google Scholar
• Angel JB, High K, Rhame F et al.; Leukine HIV Study Group. Phase III study of granulocyte–macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. AIDS14, 387–395 (2000).
   PubMed Web of Science ®Google Scholar